Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board), National Institute for Occupational Safety and Health (NIOSH), 12456-12457 [2017-04101]

Download as PDF 12456 Federal Register / Vol. 82, No. 41 / Friday, March 3, 2017 / Notices the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2017–04104 Filed 3–2–17; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention mstockstill on DSK3G9T082PROD with NOTICES Advisory Board on Radiation and Worker Health (ABRWH or Advisory Board), National Institute for Occupational Safety and Health (NIOSH) In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92–463), and pursuant to the requirements of 42 CFR 83.15(a), the Centers for Disease Control and Prevention (CDC), announces the following meeting of the aforementioned committee: Times and Dates: 8:15 a.m.–5:30 p.m., CDT, March 22, 2017 8:15 a.m.–1:00 p.m., CDT, March 23, 2017 Public Comment Time and Date: 5:30 p.m.–6:30 p.m.*, CDT, March 22, 2017 * Please note that the public comment period may end before the time indicated, following the last call for comments. Members of the public who wish to provide public comments should plan to attend the public comment session at the start time listed. Place: Embassy Suites By Hilton Chicago Naperville, 1823 Abriter Court, Naperville, Illinois 60563; Phone: 630– 799–5900; Fax: 630–799–3900. Status: Open to the public, limited only by the space available. The meeting space accommodates approximately 100 people. Audio Conference Call via FTS Conferencing. The USA toll-free, dial-in number is 1–866–659–0537 with a pass code of 9933701. Skype Meeting CONNECTION: https:// webconf.cdc.gov/zab6/yzdq02pl?sl=1. Background: The Advisory Board was established under the Energy Employees Occupational Illness Compensation Program Act of 2000 to advise the President on a variety of policy and technical functions required to implement and effectively manage the new compensation program. Key functions of the Advisory Board include providing advice on the development of probability of causation guidelines VerDate Sep<11>2014 16:42 Mar 02, 2017 Jkt 241001 which have been promulgated by the Department of Health and Human Services (HHS) as a final rule, advice on methods of dose reconstruction which have also been promulgated by HHS as a final rule, advice on the scientific validity and quality of dose estimation and reconstruction efforts being performed for purposes of the compensation program, and advice on petitions to add classes of workers to the Special Exposure Cohort (SEC). In December 2000, the President delegated responsibility for funding, staffing, and operating the Advisory Board to HHS, which subsequently delegated this authority to the CDC. NIOSH implements this responsibility for CDC. The charter was issued on August 3, 2001, renewed at appropriate intervals, rechartered on March 22, 2016 pursuant to Executive Order 13708, and will expire on September 30, 2017. Purpose: This Advisory Board is charged with (a) providing advice to the Secretary, HHS, on the development of guidelines under Executive Order 13179; (b) providing advice to the Secretary, HHS, on the scientific validity and quality of dose reconstruction efforts performed for this program; and (c) upon request by the Secretary, HHS, advising the Secretary on whether there is a class of employees at any Department of Energy facility who were exposed to radiation but for whom it is not feasible to estimate their radiation dose, and on whether there is reasonable likelihood that such radiation doses may have endangered the health of members of this class. Matters for Discussion: The agenda for the Advisory Board meeting includes: NIOSH Program Update; Department of Labor Program Update; Department of Energy Program Update; Dose Reconstruction Review Methods for Future Reviews; SEC Petitions Update; Site Profile reviews for Argonne East (Naperville, Illinois), General Steel Industries (Granite City, Illinois) and Kansas City Plant (Kansas City, Missouri); SEC petitions for: Carborundum Company (1943–1976; Niagara Falls, New York), Los Alamos National Laboratory (1996–2005; Los Alamos, New Mexico), Idaho National Laboratory (1949–1970; Scoville, Idaho), Rocky Flats Plant (1984–2005; Golden, Colorado), Savannah Rivers Site (1973– 2007; Aiken, South Carolina); and Board Work Sessions. The agenda is subject to change as priorities dictate. In the event an individual cannot attend, written comments may be submitted to the contact person below well in advance of the meeting. Any written comments received will be PO 00000 Frm 00030 Fmt 4703 Sfmt 4703 provided at the meeting in accordance with the redaction policy provided below. Policy on Redaction of Board Meeting Transcripts (Public Comment): (1) If a person making a comment gives his or her personal information, no attempt will be made to redact the name; however, NIOSH will redact other personally identifiable information, such as contact information, social security numbers, case numbers, etc., of the commenter. (2) If an individual in making a statement reveals personal information (e.g., medical or employment information) about themselves that information will not usually be redacted. The NIOSH Freedom of Information Act (FOIA) coordinator will, however, review such revelations in accordance with the Federal Advisory Committee Act and if deemed appropriate, will redact such information. (3) If a commenter reveals personal information concerning a living third party, that information will be reviewed by the NIOSH FOIA coordinator, and upon determination, if deemed appropriated, such information will be redacted, unless the disclosure is made by the third party’s authorized representative under the Energy Employees Occupational Illness Compensation Program Act (EEOICPA) program. (4) In general, information concerning a deceased third party may be disclosed; however, such information will be redacted if (a) the disclosure is made by an individual other than the survivor claimant, a parent, spouse, or child, or the authorized representative of the deceased third party; (b) if it is unclear whether the third party is living or deceased; or (c) the information is unrelated or irrelevant to the purpose of the disclosure. The Board will take reasonable steps to ensure that individuals making public comment are aware of the fact that their comments (including their name, if provided) will appear in a transcript of the meeting posted on a public Web site. Such reasonable steps include: (a) A statement read at the start of each public comment period stating that transcripts will be posted and names of speakers will not be redacted; (b) A printed copy of the statement mentioned in (a) above will be displayed on the table where individuals sign up to make public comments; (c) A statement such as outlined in (a) above will also appear with the agenda for a Board Meeting when it is posted on the NIOSH Web site; (d) A statement such as in (a) above will appear in the Federal Register E:\FR\FM\03MRN1.SGM 03MRN1 Federal Register / Vol. 82, No. 41 / Friday, March 3, 2017 / Notices Notice that announces Board and Subcommittee meetings. Contact Person for More Information: Theodore Katz, Designated Federal Officer, NIOSH, CDC, 1600 Clifton Road NE., MS E–20, Atlanta, Georgia 30329, telephone: (513) 533–6800, toll free: 1– 800–CDC–INFO, email: dcas@cdc.gov. The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register Notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Elaine L. Baker, Director, Management Analysis and Services Office, Centers for Disease Control and Prevention. [FR Doc. 2017–04101 Filed 3–2–17; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2017–N–0965] Joint Meeting of the Nonprescription Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments AGENCY: Food and Drug Administration, HHS. Notice; establishment of a public docket; request for comments. ACTION: The Food and Drug Administration (FDA) announces a forthcoming public advisory committee meeting of the Nonprescription Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee. The general function of the committees is to provide advice and recommendations to the Agency on FDA’s regulatory issues. The meeting will be open to the public. FDA is establishing a docket for public comment on this document. DATES: The meeting will be held on April 4, 2017, from 8 a.m. to 5 p.m. ADDRESSES: Tommy Douglas Conference Center, the Ballroom, 10000 New Hampshire Ave., Silver Spring, MD 20903. The conference center’s telephone number is 240–645–4000. Answers to commonly asked questions including information regarding special accommodations due to a disability, visitor parking, and transportation may be accessed at: https://www.fda.gov/ mstockstill on DSK3G9T082PROD with NOTICES SUMMARY: VerDate Sep<11>2014 16:42 Mar 02, 2017 Jkt 241001 AdvisoryCommittees/ AboutAdvisoryCommittees/ ucm408555.htm. You may submit comments as follows: Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand delivery/Courier (for written/paper submissions): Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Division of Dockets Management, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2017–N–0965 for ‘‘Joint Meeting of the Nonprescription Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments.’’ Received comments will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. PO 00000 Frm 00031 Fmt 4703 Sfmt 4703 12457 • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Division of Dockets Management. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.gpo.gov/ fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https:// www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: Moon Hee V. Choi, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, rm. 2417, Silver Spring, MD 20993–0002, 301– 796–9001, FAX: 301–847–8533, email: NDAC@fda.hhs.gov, or FDA Advisory Committee Information Line, 1–800– 741–8138 (301–443–0572 in the Washington, DC area). A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the Agency’s Web site at https:// www.fda.gov/AdvisoryCommittees/ default.htm and scroll down to the E:\FR\FM\03MRN1.SGM 03MRN1

Agencies

[Federal Register Volume 82, Number 41 (Friday, March 3, 2017)]
[Notices]
[Pages 12456-12457]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-04101]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Advisory Board on Radiation and Worker Health (ABRWH or Advisory 
Board), National Institute for Occupational Safety and Health (NIOSH)

    In accordance with section 10(a)(2) of the Federal Advisory 
Committee Act (Pub. L. 92-463), and pursuant to the requirements of 42 
CFR 83.15(a), the Centers for Disease Control and Prevention (CDC), 
announces the following meeting of the aforementioned committee:
    Times and Dates:
8:15 a.m.-5:30 p.m., CDT, March 22, 2017
8:15 a.m.-1:00 p.m., CDT, March 23, 2017
    Public Comment Time and Date:
5:30 p.m.-6:30 p.m.*, CDT, March 22, 2017
    * Please note that the public comment period may end before the 
time indicated, following the last call for comments. Members of the 
public who wish to provide public comments should plan to attend the 
public comment session at the start time listed.
    Place: Embassy Suites By Hilton Chicago Naperville, 1823 Abriter 
Court, Naperville, Illinois 60563; Phone: 630-799-5900; Fax: 630-799-
3900.
    Status: Open to the public, limited only by the space available. 
The meeting space accommodates approximately 100 people. Audio 
Conference Call via FTS Conferencing. The USA toll-free, dial-in number 
is 1-866-659-0537 with a pass code of 9933701. Skype Meeting 
CONNECTION: https://webconf.cdc.gov/zab6/yzdq02pl?sl=1.
    Background: The Advisory Board was established under the Energy 
Employees Occupational Illness Compensation Program Act of 2000 to 
advise the President on a variety of policy and technical functions 
required to implement and effectively manage the new compensation 
program. Key functions of the Advisory Board include providing advice 
on the development of probability of causation guidelines which have 
been promulgated by the Department of Health and Human Services (HHS) 
as a final rule, advice on methods of dose reconstruction which have 
also been promulgated by HHS as a final rule, advice on the scientific 
validity and quality of dose estimation and reconstruction efforts 
being performed for purposes of the compensation program, and advice on 
petitions to add classes of workers to the Special Exposure Cohort 
(SEC).
    In December 2000, the President delegated responsibility for 
funding, staffing, and operating the Advisory Board to HHS, which 
subsequently delegated this authority to the CDC. NIOSH implements this 
responsibility for CDC. The charter was issued on August 3, 2001, 
renewed at appropriate intervals, rechartered on March 22, 2016 
pursuant to Executive Order 13708, and will expire on September 30, 
2017.
    Purpose: This Advisory Board is charged with (a) providing advice 
to the Secretary, HHS, on the development of guidelines under Executive 
Order 13179; (b) providing advice to the Secretary, HHS, on the 
scientific validity and quality of dose reconstruction efforts 
performed for this program; and (c) upon request by the Secretary, HHS, 
advising the Secretary on whether there is a class of employees at any 
Department of Energy facility who were exposed to radiation but for 
whom it is not feasible to estimate their radiation dose, and on 
whether there is reasonable likelihood that such radiation doses may 
have endangered the health of members of this class.
    Matters for Discussion: The agenda for the Advisory Board meeting 
includes: NIOSH Program Update; Department of Labor Program Update; 
Department of Energy Program Update; Dose Reconstruction Review Methods 
for Future Reviews; SEC Petitions Update; Site Profile reviews for 
Argonne East (Naperville, Illinois), General Steel Industries (Granite 
City, Illinois) and Kansas City Plant (Kansas City, Missouri); SEC 
petitions for: Carborundum Company (1943-1976; Niagara Falls, New 
York), Los Alamos National Laboratory (1996-2005; Los Alamos, New 
Mexico), Idaho National Laboratory (1949-1970; Scoville, Idaho), Rocky 
Flats Plant (1984-2005; Golden, Colorado), Savannah Rivers Site (1973-
2007; Aiken, South Carolina); and Board Work Sessions.
    The agenda is subject to change as priorities dictate.
    In the event an individual cannot attend, written comments may be 
submitted to the contact person below well in advance of the meeting. 
Any written comments received will be provided at the meeting in 
accordance with the redaction policy provided below.
    Policy on Redaction of Board Meeting Transcripts (Public Comment):
    (1) If a person making a comment gives his or her personal 
information, no attempt will be made to redact the name; however, NIOSH 
will redact other personally identifiable information, such as contact 
information, social security numbers, case numbers, etc., of the 
commenter.
    (2) If an individual in making a statement reveals personal 
information (e.g., medical or employment information) about themselves 
that information will not usually be redacted. The NIOSH Freedom of 
Information Act (FOIA) coordinator will, however, review such 
revelations in accordance with the Federal Advisory Committee Act and 
if deemed appropriate, will redact such information.
    (3) If a commenter reveals personal information concerning a living 
third party, that information will be reviewed by the NIOSH FOIA 
coordinator, and upon determination, if deemed appropriated, such 
information will be redacted, unless the disclosure is made by the 
third party's authorized representative under the Energy Employees 
Occupational Illness Compensation Program Act (EEOICPA) program.
    (4) In general, information concerning a deceased third party may 
be disclosed; however, such information will be redacted if (a) the 
disclosure is made by an individual other than the survivor claimant, a 
parent, spouse, or child, or the authorized representative of the 
deceased third party; (b) if it is unclear whether the third party is 
living or deceased; or (c) the information is unrelated or irrelevant 
to the purpose of the disclosure. The Board will take reasonable steps 
to ensure that individuals making public comment are aware of the fact 
that their comments (including their name, if provided) will appear in 
a transcript of the meeting posted on a public Web site. Such 
reasonable steps include: (a) A statement read at the start of each 
public comment period stating that transcripts will be posted and names 
of speakers will not be redacted; (b) A printed copy of the statement 
mentioned in (a) above will be displayed on the table where individuals 
sign up to make public comments; (c) A statement such as outlined in 
(a) above will also appear with the agenda for a Board Meeting when it 
is posted on the NIOSH Web site; (d) A statement such as in (a) above 
will appear in the Federal Register

[[Page 12457]]

Notice that announces Board and Subcommittee meetings.
    Contact Person for More Information: Theodore Katz, Designated 
Federal Officer, NIOSH, CDC, 1600 Clifton Road NE., MS E-20, Atlanta, 
Georgia 30329, telephone: (513) 533-6800, toll free: 1-800-CDC-INFO, 
email: dcas@cdc.gov.
    The Director, Management Analysis and Services Office, has been 
delegated the authority to sign Federal Register Notices pertaining to 
announcements of meetings and other committee management activities, 
for both the Centers for Disease Control and Prevention and the Agency 
for Toxic Substances and Disease Registry.

Elaine L. Baker,
Director, Management Analysis and Services Office, Centers for Disease 
Control and Prevention.
[FR Doc. 2017-04101 Filed 3-2-17; 8:45 am]
BILLING CODE 4163-18-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.